This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.
This is a Phase II randomized, double-blind, placebo-controlled, clinical study to evaluate
the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2
infection who are receiving standard supportive care in an outpatient setting.
Study eligibility will be assessed during screening. All study participants must sign a
written informed consent and satisfy the inclusion and exclusion criteria for the study.
Confirmation of SARS-CoV-2 infection, medical history, and current medication will be
assessed for each consenting participant at screening.
Study participants will be randomized in a 1:1 ratio, to receive study therapy (either
LAM-002A, 125 mg [5 capsules/dose]) PO BID or placebo [5 capsules/dose] PO BID) for 10 days.
Participants who experience an adverse event (AE) considered to be related to study therapy
may have a decrease in study dose of LAM-002A to 100 mg [4 capsules/dose]) PO BID or placebo
[4 capsules/dose] PO BID). After the start of treatment on Day 1, participants will be
followed at Days 4,6,8,11,22, and 28. Days 6,8, and 22 will be phone visits. Participants can
withdraw from the study therapy or study participation at any time.
The study will incorporate an interim safety analysis after the first 30 participants (15 on
LAM-002A and 15 on placebo) have completed treatment and have been followed up for 11 days
post-first dose. Recruitment and randomization will continue while this analysis is
conducted. Recommendations from an independent Data Safety Monitoring Board (DSMB) will be
used for decisions of early termination or study design adaptations.
Non-parametric and parametric statistical analysis will be conducted, as appropriate. For the
comparison of the LAM-002A active arm and the control arm for the primary endpoint and
secondary endpoints of drug effect, appropriate methods will be employed. Baseline subject
characteristics, study therapy administration/compliance, safety, supportive care
administration, and pharmacokinetics will be analyzed descriptively.
Drug: Apilimod Dimesylate Capsule
LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
Other: Placebo
Microcrystalline cellulose in Swedish orange, Size 0 capsules
Inclusion Criteria:
1. Written documentation of SARS-CoV-2 infection confirmed by a validated test.
2. Presence of greater than or equal to ≥1 of the following COVID-19-related symptoms
indicating mild disease: fever (temperature ≥100.4), anosmia (loss of taste or smell),
cough, sore throat, gastrointestinal complaints (e.g. nausea, vomiting, or diarrhea),
chills, congestion, or runny nose, headaches, muscle or body aches, fatigue, or
asymptomatic patients who have tested positive for COVID-19 via a validated test
within the past 4 days.
3. If symptomatic, symptom onset less than or equal to ≤ 8 days.
4. For female participants of childbearing potential, a negative urine (or serum)
pregnancy test.
5. For female participants of childbearing potential, willingness to use a
protocol-recommended method of contraception from the start of the screening period
until greater than or equal to ≥30 days after the final dose of study therapy. Note: A
female subject is considered to be of childbearing potential unless she has had a
hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically
documented ovarian failure (with serum estradiol and follicle-stimulating hormone
[FSH] levels within the institutional laboratory postmenopausal range and a negative
serum or urine beta human chorionic gonadotropin [βHCG]); or is menopausal (age ≥50
years with amenorrhea for ≥6 months).
6. For male participants who can father a child and are having intercourse with females
of childbearing potential who are not using adequate contraception, willingness to use
a protocol-recommended method of contraception from the start of study therapy until
≥30 days after the final dose of study therapy and to refrain from sperm donation from
the start of study therapy until ≥90 days after administration of the final dose of
study therapy. Note: A male subject is considered able to father a child unless he has
had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.
7. Willingness and ability of the participant to ingest study drug capsules.
8. Willingness of the participant to comply with scheduled visits, drug administration
plan, protocol-specified laboratory tests, study procedures, and study restrictions.
9. Evidence of a personally signed informed consent indicating that the participant is
aware of the nature of the disease and has been informed of the procedures to be
followed, the experimental nature of the therapy, alternatives, potential risks and
discomforts, potential benefits, and other pertinent aspects of study participation.
Exclusion Criteria:
1. Respiratory rate greater than or equal to ≥20 breaths per minute.
2. Oxygen saturation by pulse oximetry less than or equal to ≤93 percent % on room air or
requirement for supplemental oxygen to maintain oxygen saturation greater than >93
percent %.
3. Total NEWS score greater than or equal to ≥6 or presence of a score of 3 on any of the
individual NEWS parameters.
4. Radiographic evidence of pulmonary infiltrates (clinical X-ray within 2 days of
referral)
5. Hepatic profile showing any of the following:
- Serum alanine aminotransferase (ALT) greater than >5 × upper limit of normal
(ULN) (CTCAE Grade greater than or equal to ≥3).
- Serum aspartate aminotransferase (AST) greater than >5 × ULN (CTCAE Grade greater
than or equal to ≥3).
- Serum bilirubin greater than >1.5 × ULN (CTCAE Grade greater than or equal to
≥2).
6. Renal profile showing an estimated creatinine clearance (eClCR) less than <30
mL/minute (with eClCR to be calculated by the method at the laboratory performing the
serum creatinine test).
7. Presence of a cancer with disease manifestations or therapy that could adversely
affect subject safety or longevity, create the potential for drug-drug interactions,
or compromise the interpretation of study results.
8. Significant cardiovascular disease (e.g. myocardial infarction, arterial
thromboembolism, cerebrovascular thromboembolism) within 1 month prior to start of
study therapy; unstable angina; symptomatic peripheral vascular disease; CTCAE Grade
greater than or equal to ≥2 congestive heart failure; or uncontrolled CTCAE Grade
greater than or equal to ≥3 hypertension (diastolic blood pressure greater than or
equal to ≥100 mmHg or systolic blood pressure greater than or equal to ≥160 mmHg)
despite antihypertensive therapy.
9. Significant screening ECG abnormalities, including atrial fibrillation/flutter, 2nd
degree atrioventricular (AV) block type II, 3rd-degree AV block, Grade greater than or
equal to ≥2 bradycardia, or corrected QT (QTc by Fridericia [QTcF]) greater than >480
msec (Grade greater than >1).
10. Gastrointestinal disease (e.g. gastric or intestinal bypass surgery, pancreatic enzyme
insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic
diarrheal illness, bowel obstruction) that might interfere with drug absorption or
with interpretation of gastrointestinal AEs.
11. Pregnancy or breastfeeding.
12. Prior solid organ transplantation.
13. Use within 5 days prior to randomization of an approved or investigational therapy
intended to treat COVID-19 (e.g. remdesivir, , anti-interleukin [IL]-6 antibodies,
therapeutic anti-SARS CoV-2 antibodies or post-convalescent plasma, anti- SARS CoV-2
vaccine, Bruton tyrosine kinase [BTK] inhibitor), use within 3 months of chloroquine
or hydroxychloroquine. Note: participants are not precluded from undergoing
evaluations involving observation, noninvasive diagnostic procedures or sampling, or
questionnaires as follow-up to a prior study or as components of a concurrent
noninterventional study.
14. Use within 5 days prior to randomization of a strong inhibitor or inducer of
cytochrome P450 (CYP) 3A4 or expected requirement for chronic use of a strong
inhibitor or inducer of CYP3A4 during study therapy.
15. Use within 5 days prior to randomization of drug that is a moderate-to-strong
substrate of CYP2C9 (including warfarin, tolbutamide, phenytoin, glimepiride) or
expected requirement for chronic use of such drugs during study therapy.
16. Use within 5 days prior to randomization of a drug known to prolong the QT interval
17. Ongoing immunosuppressive therapy including systemic or enteric corticosteroids.
(Note: At study entry, participants may be using intraarticular, inhaled, or topical
corticosteroids. During study therapy, participants may use systemic, enteric,
intraarticular, inhaled, or topical corticosteroids as required for intercurrent
conditions.)
18. Any illness, medical condition, organ system dysfunction, or social situation,
including mental illness or substance abuse, deemed by the investigator to be likely
to interfere with a participant's ability to provide informed consent, adversely
affect the participant's ability to cooperate and participate in the study, or
compromise the interpretation of study results.
Yale University
New Haven, Connecticut, United States